{
    "clinical_study": {
        "@rank": "161310", 
        "arm_group": {
            "arm_group_label": "ambrisentan", 
            "arm_group_type": "Experimental", 
            "description": "In all patients with clinically significant PoPH, ambrisentan will be administered orally using a low ascending dose regime (see below). Duration of treatment will be 12 months."
        }, 
        "brief_summary": {
            "textblock": "Portopulmonary hypertension denotes pulmonary hypertension complicating portal hypertension\n      and is present in approximately 5% of cirrhotic patients. Treatment options include\n      prostanoids, sildenafil, and the endothelin-receptor antagonists, bosentan and ambrisentan.\n\n      This study investigates the safety and efficacy of ambrisentan in portopulmonary\n      hypertension."
        }, 
        "brief_title": "Ambrisentan for Treatment of Portopulmonary Hypertension", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Portopulmonary Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "detailed_description": {
            "textblock": "Patients with clinically significant PoPH (resting mean pulmonary arterial pressure >25 mm\n      Hg, pulmonary vascular resistance >400 dynes*s*cm-5) will be offered treatment with\n      ambrisentan. Patients will be followed clinically and hemodynamically up to 12 months after\n      start of treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients with portal hypertension, age >18 years\n\n          -  Cirrhosis of any etiology; Child-Pugh class A and B\n\n          -  Noncirrhotic portal hypertension (e.g. chronic portal vein thrombosis)\n\n          -  Informed consent\n\n        Exclusion Criteria:\n\n          -  Presence of other causes for pulmonary arterial hypertension\n\n          -  History of pulmonary embolism or myocardial infarction within 6 months before study\n             start\n\n          -  Child-Pugh class C\n\n          -  Presence of hepatocellular carcinoma\n\n          -  Liver transplantation\n\n          -  HIV infection\n\n          -  Severe obstructive or restrictive pulmonary disease (predicted FEV1 or VC <65%,\n             respectively)\n\n          -  Severe dilated cardiomyopathy (EF <50%)\n\n          -  Latent left-heart insufficiency\n\n          -  Pregnancy and lactation\n\n          -  Esophageal variceal hemorrhage within the last 6 months\n\n          -  Refractory ascites\n\n          -  Hepatorenal syndrome\n\n          -  Persistent hepatic encephalopathy > grade 1\n\n          -  Bilirubin >3.0 mg/dl\n\n          -  AST and/or ALT >3x ULN\n\n          -  Creatinine >2.0 mg/dl\n\n          -  Known hypersensitivity to ambrisentan"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01733095", 
            "org_study_id": "PoPH-GRZ ambrisentan"
        }, 
        "intervention": {
            "arm_group_label": "ambrisentan", 
            "description": "Ambrisentan (Volibris 5 mg film-coated tablets, Glaxo Smith-Kline) will be started at 5 mg every other day and increased to 5 mg daily after 4 weeks if tolerated well.", 
            "intervention_name": "ambrisentan", 
            "intervention_type": "Drug", 
            "other_name": "Volibris"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 26, 2013", 
        "location": {
            "contact": {
                "email": "rudolf.stauber@medunigraz.at", 
                "last_name": "Rudolf Stauber, MD", 
                "phone": "+43-316-385-80268"
            }, 
            "contact_backup": {
                "email": "horst.olschewski@medunigraz.at", 
                "last_name": "Horst Olschewski, MD", 
                "phone": "+43-316-385-13305"
            }, 
            "facility": {
                "address": {
                    "city": "Graz", 
                    "country": "Austria", 
                    "zip": "8036"
                }, 
                "name": "Medical University of Graz"
            }, 
            "investigator": {
                "last_name": "Rudolf Stauber, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "1", 
        "official_title": "Ambrisentan for Treatment of Portopulmonary Hypertension (PoPH): a Pilot Study", 
        "overall_official": [
            {
                "affiliation": "Gastroenterology & Hepatology", 
                "last_name": "Rudolf E. Stauber, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Pulmonology", 
                "last_name": "Horst Olschewski, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Austria: Federal Office for Safety in Health Care", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "pulmonary vascular resistance", 
            "safety_issue": "No", 
            "time_frame": "week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01733095"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "mean arterial pulmonary pressure", 
                "safety_issue": "No", 
                "time_frame": "week 24"
            }, 
            {
                "measure": "hepatic venous pressure gradient", 
                "safety_issue": "No", 
                "time_frame": "week 24"
            }, 
            {
                "measure": "exercise capacity", 
                "safety_issue": "No", 
                "time_frame": "week 24, 48"
            }, 
            {
                "measure": "quality of life", 
                "safety_issue": "No", 
                "time_frame": "week 24, 48"
            }
        ], 
        "source": "Medical University of Graz", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medical University of Graz", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}